Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
610
- Development stage
- Phase 3
- Lead developer
- 3S Guojian Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Unknown Or Not Specified
01
Overview
610 is an investigational recombinant humanized monoclonal antibody developed by Sunshine Guojian Pharmaceutical as an add-on treatment for severe eosinophilic asthma. It binds and inhibits interleukin-5, blocking its interaction with the eosinophil surface receptor and reducing eosinophil-mediated inflammation. The drug is administered by subcutaneous injection and has reached phase 3 development. ([3s-guojian.com](https://www.3s-guojian.com/news/details/212.html))
- Other names
- Recombinant anti-IL-5 humanized monoclonal antibody610 - 3SBio
02
Targets
IL-5 (Interleukin 5)
Beyond the preview
Go deeper on 610.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 610.